ArticleJTCVS open2025
Two-year outcomes of endovascular repair of isolated thoracic aortic lesions using a single-branch thoracic endograft with left subclavian artery preservation.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three-year outcomes of endovascular repair of descending thoracic aortic lesions with a single-branched endograft for left subclavian artery preservation.JTCVS structural and endovascular · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thoracic endovascular aortic repair (TEVAR) has become the preferred management strategy for most pathologies involving the descending aorta. When left subclavian artery (LSA) coverage is required during TEVAR to achieve an adequate proximal landing zone (PLZ), revascularization is recommended. Branched endografts represent an alternative to surgical revascularization. Methods: Across 34 investigative sites, 13 adult patients with isolated lesions (nonaneurysm, nondissection, nontrauma) of the descending thoracic aorta requiring a zone 2 PLZ were enrolled in a prospective, nonrandomized study of a single-branched thoracic aortic endograft (GORE TAG Thoracic Branch Endoprosthesis [TBE]; WL Gore and Associates). The TBE incorporates a single side branch for LSA perfusion in zone 2. Results: The mean patient age was 65 ± 13 years, and 54% were female. Pathologies included intramural hematoma in 23% (n = 3), penetrating aortic ulcer in 39% (n = 5), and other isolated lesions in 39% (n = 5). The technical success rate of the procedure was 100%; 31% (n = 4) of the patients required distal TEVAR in addition to the TBE device for complete exclusion of their aortic pathology. The median procedure time was 142 minutes (range, 66-357 minutes). No 30-day/in-hospital mortality, stroke, paraparesis/paraplegia, or new dialysis occurred. Through 24-month core laboratory adjudicated imaging follow-up, there have been no type I/III endoleaks, LSA branch patency loss, reinterventions, or aortic enlargement (>5 mm). Conclusions: Two-year results from this multicenter, prospective, nonrandomized cohort study using an investigational single-branched thoracic endograft for maintaining LSA perfusion in patients with isolated lesions of the descending thoracic aorta demonstrate excellent perioperative and early mid-term outcomes in patients with suitable anatomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.